1. Academic Validation
  2. Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo

Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo

  • J Med Chem. 2018 Sep 27;61(18):8337-8352. doi: 10.1021/acs.jmedchem.8b00832.
Clare F Vickers 1 Ana P G Silva 2 Ajanta Chakraborty 2 Paulina Fernandez 2 Natalia Kurepina 3 Charis Saville 2 Yandi Naranjo 4 Miquel Pons 4 Laura S Schnettger 5 Maximiliano G Gutierrez 5 Steven Park 3 Barry N Kreiswith 3 David S Perlin 3 Eric J Thomas 1 Jennifer S Cavet 2 Lydia Tabernero 2
Affiliations

Affiliations

  • 1 The School of Chemistry , University of Manchester , Manchester M13 9PL , United Kingdom.
  • 2 School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre , University of Manchester , Manchester M13 9PT , United Kingdom.
  • 3 Public Health Research Institute , New Jersey Medical School, Rutgers University , 225 Warren Street , Newark , New Jersey 07103 , United States.
  • 4 Departament de Química Inorgànica i Orgànica , Universitat de Barcelona , Baldiri Reixac, 10-12 , 08028 Barcelona , Spain.
  • 5 Host-Pathogen Interactions in Tuberculosis Laboratory , The Francis Crick Institute , 1 Midland Road , NW1 1AT London , United Kingdom.
Abstract

Mycobacterium tuberculosis protein-tyrosine-phosphatase B (MptpB) is a secreted virulence factor that subverts antimicrobial activity in the host. We report here the structure-based design of selective MptpB inhibitors that reduce survival of multidrug-resistant tuberculosis strains in macrophages and enhance killing efficacy by first-line Antibiotics. Monotherapy with an orally bioavailable MptpB inhibitor reduces Infection burden in acute and chronic guinea pig models and improves the overall pathology. Our findings provide a new paradigm for tuberculosis treatment.

Figures
Products